IPO Databook: Frontera Therapeutics (HK) - Aug 2026

97 Views30 Aug 2026 10:19

SUMMARY

Incorporated in 2019, Frontera Therapeutics is a clinical-stage gene therapy company developing rAAV gene therapies for ophthalmic and cardiovascular diseases.
Frontera Therapeutics has a pipeline of six rAAV gene therapy candidates. FT-002, FT-003, and FT-001 received key regulatory designations.
As of June 30, 2026, cash and cash equivalents were US$16,973 thousand. Net assets decreased to US$24.2 million.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream